Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Interest Expenses history runs 14 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 529.45% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 365.56% increase from a year earlier, with the FY2025 full-year figure at $316.8 million, up 51.95% from the prior year.
• Interest Expenses improved to $3.5 million in Q1 2026 per VRDN's latest filing, from $3.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $15.5 million in Q3 2024 and bottomed at -$25000.0 in Q4 2022.
• The 5-year median for Interest Expenses is $555000.0 (2025), against an average of $2.0 million.
• Across the five-year window, Interest Expenses plunged 112.5% in 2022 and soared 2487.33% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$25000.0 in 2022, then jumped by 1700.0% to $400000.0 in 2023, then slumped by 65.0% to $140000.0 in 2024, then jumped by 2244.29% to $3.3 million in 2025, then gained by 5.48% to $3.5 million in 2026.
• Per Business Quant, the three latest VRDN Interest Expenses figures stand at $3.5 million (Q1 2026), $3.3 million (Q4 2025), and $560000.0 (Q3 2025).